Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - trazodone hydrochloride - kapseli, kova - 50 mg - tratsodoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

zambon s.p.a. - fosfomycine trometamol - rakeet oraaliliuosta varten, annospussi - 3 g - fosfomysiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - trazodoni hydrochloridum - kapseli, kova - 25 mg - tratsodoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - trazodoni hydrochloridum - kapseli, kova - 100 mg - tratsodoni

Euroopan unioni - suomi - EMA (European Medicines Agency)

zambon spa - safinamidin metaanisulfonaatti - parkinsonin tauti - parkinson-lääkkeet - xadago on ilmoitettu hoito aikuispotilailla, joilla on idiopaattinen parkinsonin taudista (pd) lisää-hoitoa vakaa annos levodopa (levodopan) yksin tai yhdessä muiden pd lääkkeiden-loppuvaiheen vaihteleva potilaille.

Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zambon group s.p.a. - fosfomycinum trometamolum - rakeet - 3 g - fosfomysiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - clarithromycinum - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini